Tamil Nadu cancels licence of Sresan Pharma, orders shutdown

Written By :  Ruchika Sharma
Published On 2025-10-13 10:35 GMT   |   Update On 2025-10-13 10:35 GMT
Advertisement

Chennai: Tamil Nadu-based Sresan Pharmaceuticals, the company behind the adulterated Coldrif cough syrup linked to child deaths in Madhya Pradesh, has been ordered to shut down and its manufacturing licence has been completely revoked, the state government confirmed on Monday.

An inspection by the state Drug Control Department had found that the company’s cough syrup contained a dangerous 48.6% Diethylene Glycol (DEG) — a toxic chemical.

Advertisement
As per PTI, the officials had also found that the company lacked proper good manufacturing practices (GMP) and good laboratory practices (GLP), and they recorded over 300 critical and major violations.
The company’s owner, G Ranganathan, was recently arrested by a special investigation team from Madhya Pradesh.
Earlier in the day, a team from the Enforcement Directorate raided the premises of Sresan Pharmaceuticals and some officials, in a Prevention of Money Laundering Act (PMLA) case.
“The drug manufacturing license of Sresan Pharmaceuticals has been completely cancelled, and the company has been closed. Orders have been given to conduct a detailed inspection of other drug manufacturing companies located in Tamil Nadu,” the government said in a release here.

Earlier, the CDSCO visited Chhindwara as part of a central team, which was deputed to the city and Nagpur.

During the visit on September 27, the CDSCO picked six samples from Chhindwara and the MPFDA picked 13 samples. The 19 samples were of 19 different medicines that were consumed by children hospitalised with similar symptoms.

The samples included cough syrups, antibiotics, antipyretics and ondansetron etc.

On Friday, Union Health Secretary Punya Salila Srivastava, convened a high-level meeting with all states and Union territories to review compliance with drug quality norms and promote the rational use of cough syrups, especially in paediatric populations.

In the meeting, the need for strict action in this regard was underlined.

Official sources said that Sresan Pharma is neither WHO GMP certified nor meets the requirements of Revised Schedule M, as is required by the gazette notification dated December 28, 2023.

Read also: Coldrif fallout: How a Pharma firm skipped India's Drug Watchdog inspections

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News